Endothelial cell‐derived angiopoietin‐2 is a therapeutic target in treatment‐naive and bevacizumab‐resistant glioblastoma

Glioblastoma multiforme (GBM) is treated by surgical resection followed by radiochemotherapy. Bevacizumab is commonly deployed for anti‐angiogenic therapy of recurrent GBM; however, innate immune cells have been identified as instigators of resistance to bevacizumab treatment. We identified angiopoi...

Descripción completa

Detalles Bibliográficos
Autores principales: Scholz, Alexander, Harter, Patrick N, Cremer, Sebastian, Yalcin, Burak H, Gurnik, Stefanie, Yamaji, Maiko, Di Tacchio, Mariangela, Sommer, Kathleen, Baumgarten, Peter, Bähr, Oliver, Steinbach, Joachim P, Trojan, Jörg, Glas, Martin, Herrlinger, Ulrich, Krex, Dietmar, Meinhardt, Matthias, Weyerbrock, Astrid, Timmer, Marco, Goldbrunner, Roland, Deckert, Martina, Braun, Christian, Schittenhelm, Jens, Frueh, Jochen T, Ullrich, Evelyn, Mittelbronn, Michel, Plate, Karl H, Reiss, Yvonne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2015
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4718155/
https://www.ncbi.nlm.nih.gov/pubmed/26666269
http://dx.doi.org/10.15252/emmm.201505505

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4718155/
https://www.ncbi.nlm.nih.gov/pubmed/26666269
http://dx.doi.org/10.15252/emmm.201505505

Ejemplares similares